Literature DB >> 18931668

Linking SNPs to CAG repeat length in Huntington's disease patients.

Wanzhao Liu1, Lori A Kennington, H Diana Rosas, Steven Hersch, Jang-Ho Cha, Phillip D Zamore, Neil Aronin.   

Abstract

Allele-specific silencing using small interfering RNAs targeting heterozygous single-nucleotide polymorphisms (SNPs) is a promising therapy for human trinucleotide repeat diseases such as Huntington's disease. Linking SNP identities to the two HTT alleles, normal and disease-causing, is a prerequisite for allele-specific RNA interference. Here we describe a method, SNP linkage by circularization (SLiC), to identify linkage between CAG repeat length and nucleotide identity of heterozygous SNPs using Huntington's disease patient peripheral blood samples.

Entities:  

Mesh:

Year:  2008        PMID: 18931668      PMCID: PMC2587014          DOI: 10.1038/nmeth.1261

Source DB:  PubMed          Journal:  Nat Methods        ISSN: 1548-7091            Impact factor:   28.547


  14 in total

1.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

2.  Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.

Authors:  Hongliu Ding; Dianne S Schwarz; Alex Keene; El Bachir Affar; Laura Fenton; Xugang Xia; Yang Shi; Phillip D Zamore; Zuoshang Xu
Journal:  Aging Cell       Date:  2003-08       Impact factor: 9.304

3.  Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.

Authors:  Natasha J Caplen; J Paul Taylor; Victoria S Statham; Fumiaki Tanaka; Andrew Fire; Richard A Morgan
Journal:  Hum Mol Genet       Date:  2002-01-15       Impact factor: 6.150

4.  Genetic applications of an inverse polymerase chain reaction.

Authors:  H Ochman; A S Gerber; D L Hartl
Journal:  Genetics       Date:  1988-11       Impact factor: 4.562

5.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.

Authors:  R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue.

Authors:  S Zeitlin; J P Liu; D L Chapman; V E Papaioannou; A Efstratiadis
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Fear of health insurance loss among individuals at risk for Huntington disease.

Authors:  Emily Oster; E Ray Dorsey; Jan Bausch; Aileen Shinaman; Elise Kayson; David Oakes; Ira Shoulson; Kimberly Quaid
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

8.  Mouse Huntington's disease homolog mRNA levels: variation and allele effects.

Authors:  Karen T Dixon; Jamie A Cearley; Jesse M Hunter; Peter J Detloff
Journal:  Gene Expr       Date:  2004

9.  Inactivation of the mouse Huntington's disease gene homolog Hdh.

Authors:  M P Duyao; A B Auerbach; A Ryan; F Persichetti; G T Barnes; S M McNeil; P Ge; J P Vonsattel; J F Gusella; A L Joyner
Journal:  Science       Date:  1995-07-21       Impact factor: 47.728

10.  Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals.

Authors:  G B Landwehrmeyer; S M McNeil; L S Dure; P Ge; H Aizawa; Q Huang; C M Ambrose; M P Duyao; E D Bird; E Bonilla
Journal:  Ann Neurol       Date:  1995-02       Impact factor: 10.422

View more
  17 in total

1.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

2.  Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.

Authors:  Masaki Takahashi; Shoko Watanabe; Miho Murata; Hirokazu Furuya; Ichiro Kanazawa; Keiji Wada; Hirohiko Hohjoh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 3.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

4.  Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.

Authors:  Lisa M Stanek; Sergio P Sardi; Bryan Mastis; Amy R Richards; Christopher M Treleaven; Tatyana Taksir; Kuma Misra; Seng H Cheng; Lamya S Shihabuddin
Journal:  Hum Gene Ther       Date:  2014-03-21       Impact factor: 5.695

Review 5.  Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

Authors:  P Hemachandra Reddy; Ulziibat P Shirendeb
Journal:  Biochim Biophys Acta       Date:  2011-11-04

6.  Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

Authors:  Jeffrey B Carroll; Simon C Warby; Amber L Southwell; Crystal N Doty; Sarah Greenlee; Niels Skotte; Gene Hung; C Frank Bennett; Susan M Freier; Michael R Hayden
Journal:  Mol Ther       Date:  2011-10-04       Impact factor: 11.454

Review 7.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

8.  Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?

Authors:  Wanzhao Liu; Edith L Pfister; Lori A Kennington; Kathryn O Chase; Christian Mueller; Marian DiFiglia; Neil Aronin
Journal:  J Huntingtons Dis       Date:  2016

9.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Authors:  Ryan L Boudreau; Jodi L McBride; Inês Martins; Shihao Shen; Yi Xing; Barrie J Carter; Beverly L Davidson
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

10.  Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

Authors:  Edith L Pfister; Lori Kennington; Juerg Straubhaar; Sujata Wagh; Wanzhou Liu; Marian DiFiglia; Bernhard Landwehrmeyer; Jean-Paul Vonsattel; Phillip D Zamore; Neil Aronin
Journal:  Curr Biol       Date:  2009-04-09       Impact factor: 10.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.